Comparative safety of istradefylline in Parkinson's disease: A systematic review of randomized controlled trials and real-world studies.

ABSTRACT:

Introduction

Istradefylline offers a novel mechanism (adenosine A_2A receptor antagonism) to treat OFF episodes in Parkinson's disease (PD). It may potentially offer improved tolerability versus other adjuncts, but comparative safety data are lacking.

Methods

A systematic review and Bayesian network meta-analysis (NMA) incorporating RCTs of PD adjuncts until January 10, 2024, was conducted to estimate relative safety. Inconsistency was assessed and heterogeneity evaluated by global I²-statistic and between-study heterogeneity. Incidences of safety outcomes were summarized from RWE identified according to the same criteria.

Results

100 RCTs and 55 RWE publications were identified; 76 RCTs were included in NMAs. Istradefylline demonstrated lo

SUBMITTER: Bette S 

PROVIDER: S-EPMC11904592 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature